Patents Assigned to Baylor College of Medicine
  • Patent number: 10799333
    Abstract: A magnet assisted surgical device, system, and method employs magnetic sections, catheters, and guidewires to modify tubular stentgrafts in-situ. One example application provides a more reliable way for surgeons to modify stentgrafts insitu to allow blood flow to continue to branching blood vessels that would otherwise be blocked by the stentgraft itself. One such method includes placing a tip section of the device in the desired location, deploying a stentgraft, placing a magnetic device inside the stentgraft, connecting the magnetic device to the tip section, and excising the portion of the stentgraft held between the magnet and the tip section.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: October 13, 2020
    Assignees: Baylor College of Medicine, Texas Heart Institute
    Inventors: Ramyar Gilani, Ourania Preventza, William E. Cohn
  • Patent number: 10786549
    Abstract: Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: September 29, 2020
    Assignee: Baylor College of Medicine
    Inventors: Maksim Mamonkin, Malcolm K. Brenner
  • Patent number: 10772914
    Abstract: Methods for generating/expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen are disclosed, the methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 15, 2020
    Assignee: Baylor College of Medicine
    Inventors: Cliona M. Rooney, Sandhya Sharma
  • Patent number: 10716818
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: July 21, 2020
    Assignee: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Publication number: 20200222453
    Abstract: Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.
    Type: Application
    Filed: April 30, 2018
    Publication date: July 16, 2020
    Applicants: WILLIAM MARSH RICE UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, BAYLOR COLLEGE OF MEDICINE, HOUSTON METHODIST RESEARCH INSTITUTE, THE UNITED STATES GOVERNMENT
    Inventors: James M. TOUR, Lizanne NILEWSKI, William SIKKEMA, Kimberly MENDOZA, Thomas Andrew KENT, William DALMEIDA, Jr., Paul J. DERRY, Ah-Lim TSAI, Muralidhar L. HEGDE, Prakash DHARMALINGAM, Pavana Dixit HEGDE, Sankar MITRA, Joy MITRA
  • Publication number: 20200216810
    Abstract: An isolated human NKT cell or a plurality of cells thereof, having reduced or no detectable expression of endogenous beta-2-microglobulin (B2M); endogenous MHC class II-associated invariant chain (Ii); or both. Methods to generate the cell or cells, and methods of treatment using the cell or cells are also provided.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 9, 2020
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Jingling Jin, Bin Liu
  • Publication number: 20200209261
    Abstract: Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.
    Type: Application
    Filed: May 11, 2018
    Publication date: July 2, 2020
    Applicant: Baylor College of Medicine
    Inventors: Robert Allen Britton, Jeffrey David Galley
  • Patent number: 10695401
    Abstract: Embodiments of the disclosure include methods and compositions for treating or preventing acute inflammation using soluble vimentin. In specific embodiments, a vimentin derivative comprising the rod domain is utilized for treating or preventing any disease in which a decrease in leukocyte adhesion is therapeutic. In specific embodiments, a fragment of vimentin that comprises part or all of the rod domain is employed.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: June 30, 2020
    Assignee: Baylor College of Medicine
    Inventors: Fong Wilson Lam, Qi Da, Miguel A. Cruz
  • Patent number: 10676455
    Abstract: Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 9, 2020
    Assignee: Baylor College of Medicine
    Inventors: David J. Tweardy, Moses M. Kasembeli, Marvin X. Xu, Thomas Kristian Eckols
  • Publication number: 20200085824
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 19, 2020
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • Publication number: 20200078389
    Abstract: Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders and syndromes. Such MECP2 associated disorders include MECP2 duplication syndrome.
    Type: Application
    Filed: August 8, 2019
    Publication date: March 12, 2020
    Applicants: Ionis Pharmaceuticals, Inc., Baylor College of Medicine
    Inventors: Susan M. Freier, Huda Y. Zoghbi, Ezequiel Sztainberg
  • Patent number: 10584158
    Abstract: Embodiments of the disclosure concern cell therapy methods and compositions utilizing cells expressing at least a chimeric TGF? receptor including the exodomain of a TGF?II receptor and an endodomain that is not from TGF? receptor, thereby converting the negative signal of TGF? for T cell proliferation into a T cell activation signal. In at least certain aspects, cells harboring the chimeric TGF? receptor also harbor one or more chimeric antigen receptors.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: March 10, 2020
    Assignee: Baylor College of Medicine
    Inventors: Juan Fernando Vera Valdes, Cliona M. Rooney, Ann Marie Leen, Norihiro Watanabe
  • Publication number: 20200071300
    Abstract: Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds are also useful in preventing cardiac hypertrophy and collagen deposition and improving cardiac post-infarction function.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Applicant: Baylor College of Medicine
    Inventors: Bert W. O'Malley, David Michael Lonard, Yongcheng Song
  • Patent number: 10548921
    Abstract: Disclosed are compositions and methods related to rendering ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. Tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulatory/activating signal. The T cells employ a chimeric antigen receptor having exodomains for IL10, IL13 and/or IL4 fused with the signal transducing endodomains for IL2 and/or IL7.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: February 4, 2020
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Ann Marie Leen, Juan F. Vera
  • Patent number: 10533156
    Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: January 14, 2020
    Assignees: Baylor College of Medicine, Wilson Wolf Manufacturing
    Inventors: Juan F. Vera, Cliona M. Rooney, Ann M. Leen, John R. Wilson
  • Publication number: 20200000581
    Abstract: One aspect of the invention provides and artificial, flexible valve indlucding: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. The plurality of leaflets form a plurality of coaptation regions between two adjacent leaflets. The coaptation regions include extensions along a z-axis and adapted and are configured to form a releasable, but substantially complete seal when the leaflets are in a closed position. Another aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. Each of the plurality of leaflets terminates in a commissure line. The commissure lines devi-ate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.
    Type: Application
    Filed: September 6, 2019
    Publication date: January 2, 2020
    Applicants: Baylor College of Medicine, William Marsh Rice University
    Inventors: Henri JUSTINO, Daniel HARRINGTON, Kwonsoo CHUN
  • Publication number: 20190389943
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: July 1, 2019
    Publication date: December 26, 2019
    Applicants: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 10512656
    Abstract: The present invention relates to compositions and methods of treating lysosomal storage diseases and methods of using trehalose.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 24, 2019
    Assignee: Baylor College of Medicine
    Inventor: Marco Sardiello
  • Patent number: 10512647
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 24, 2019
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • Publication number: 20190380891
    Abstract: One aspect of the invention provides a mobile clinic including: an intermodal container defining at least a first opening and a second opening; a partition wall located within the intermodal container, the partition wall separating the intermodal container into an anteroom and a treatment room; and an access control device programmed to prevent passage from the anteroom into the treatment room until a user's donning of personal protective equipment is verified. Another aspect of the invention provides a collapsible structure including: a rigid base; a rigid roof; one or more collapsible walls extending between the floor and the base; and an erector system comprising four cross-bars. Another aspect of the invention provides a crate including: a bottom panel; a top panel; and a plurality of walls, wherein at least two of said plurality of walls including one or more conduits.
    Type: Application
    Filed: August 28, 2019
    Publication date: December 19, 2019
    Applicant: Baylor College of Medicine
    Inventors: Sharmila Anandasabapathy, Sarah Michel, Caroline Popper